In Memoriam of the 4CC Co-Founder, Professor Henry Krum
Professor Henry Krum, the co-founder of the 4 Corners of Cardiology Meeting, passed away on Saturday 28th November 2015. Henry was an internationally renowned researcher, teacher and mentor who has helped shape our thinking, right through from basic cardiovascular physiology to large international clinical trials.
Prof Henry Krum
Prof Henry Krum was a recognised leader in cardiovascular therapeutics, particularly in the area of novel cardiovascular drug therapies. This is attested to by his publication record, grant success and invitations to give plenary talks at major international meetings. He was the Editor-in-Chief, Associate Editor and/or Editorial Board member of many international cardiovascular therapeutics journals and former President of the Asian Pacific Society of Heart Failure. Prof Krum had been Chairman and Executive Committee member of numerous international clinical trials as well as serving on Endpoint Committees and DSMBs for such trials. He was appointed Study Chairman of a 7000 patient global heart failure trial. He has in addition, led many investigator-initiated trials of cardiovascular therapeutic agents.
The members of the 6th International 4 Corners of Cardiology 2022 Organising Committee:
Prof David Hare
Professor David Hare studied at the University of Melbourne and Guy’s Hospital, London. He has been the Coordinator of Cardiovascular Research for the University of Melbourne, is Director of Secondary Prevention, Heart Failure Service and Cardiology Research at Austin Health, has supervised over 60 research students, and each year generally averages over 500 international citations to his personal research. His research ranges from the basic molecular laboratory to randomised clinical trials and psychosocial aspects of heart disease, being the only cardiologist in the world who is also fully trained in psychiatry. He was awarded the AMRF Distinguished Scientist Medal in 2011 and is currently Research Integrity Advisor for Austin Health. In 2020 he was nominated for Australian of the Year: Australian of the Year 2020 nominees
Prof Julie Redfern
Julie Redfern is a Professor of Public Health and a clinical physiotherapist. She has led clinical trials and epidemiology studies focussed on secondary prevention along with co-design, testing and implementation of digital health interventions. She is the current Academic Leader (Researcher Development) in the Faculty of Medicine and Health, University of Sydney, co-Chair of the Exercise, Prevention and Rehabilitation Council of the CSANZ and was previously the Allied Health Council Chair and Board Representative. She serves on national and international committees, and has been awarded over $100 million in peer reviewed grants and published over 160 peer reviewed manuscripts in high ranking journals. Julie’s research aims to improve access to and engagement with secondary prevention strategies with a focus on technology and patient centred care to facilitate behaviour change.
Prof Christopher Reid
Christopher Reid is a cardiovascular epidemiologist with appointments as Research Professor in both the School of Public Health at Curtin University and the School of Public Health and Preventive Medicine, Monash University. He was appointed as a John Curtin Distinguished Professor in 2018 and is Director of the Monash and Curtin Centre’s of Cardiovascular Research and Education (CCRE) and the NHMRC Centre of Research Excellence in Cardiovascular Outcomes Improvement (2016-2020). He holds a National Health and Medical Research Council Principal Research Fellowship (2018-2022) in addition to being the Chief Investigator on an NHMRC Program Grant (2016-2020) focusing on cardiovascular disease prevention. He has been awarded over $113M as a Chief Investigator and has received continuous NHMRC funding since 2001. His major research interests include clinical outcome registries, randomized controlled trials, and epidemiological cohort studies. He has over 420 peer-reviewed publications, many of which are in leading journals including the New England Journal of Medicine, Lancet, JACC and the BMJ. He has been Study Director for the 2nd Australian National Blood Pressure (ANBP2) Study and currently a Chief Investigator for the Aspirin in Reducing Events in the Elderly (ASPREE) Study, the Statins in Reducing Events in the elderly Trial and the Australian arms of the HOPE-3, REACH and CLARIFY Registries. He is a Principal Investigator for the Victorian Cardiac Procedures Registry Project, the Melbourne Interventional Group (MIG) registry, and the ANZSCTS National Cardiac Surgical Registry. He participates as a WHO consultant for prevention of cardiovascular disease in Mongolia, Vietnam and the West Pacific region.
A/Prof John Atherton
A/Prof John Atherton is Director of Cardiology, Royal Brisbane and Women’s Hospital, Associate Professor, University of Queensland, and Adjunct Professor, Queensland University of Technology.
A/Prof Atherton was on Board of the Cardiac Society of Australia and New Zealand (CSANZ) during 2009–2015 and chairs the CSANZ Professional Ethics Standards Committee. Dr Atherton previously chaired the Asia-Pacific Acute Decompensated Heart Failure Registry Scientific Advisory Committee and the CSANZ Heart Failure Council. Dr Atherton is an appointed member of the Australian Government Medical Services Advisory Committee and provides advice to Government on public funding arrangements through Medicare.
A/Prof Atherton is Associate Editor, Heart Lung and Circulation, and sits on the editorial board for Cardiac Failure Review. Research interests include screening for presymptomatic heart disease and heart failure disease management. Contributions to service enhancement include the development of coordinated statewide heart failure disease management in Queensland, and commencing a statewide cardiac genetics clinic.
Prof John French
John’s major clinical research focus has been in the acute coronary syndromes, particularly on the assessment of myocardial reperfusion assessed by infarct-related artery blood flow, ST recovery, left ventricular function, and late clinical outcomes in patients with ST elevation myocardial infarction. He has been an active researcher having been an investigator and co-investigator in numerous randomised controlled trials and clinical trials and was on the writing committee of the HERO-2 trial. John was on the steering committee for the SHOCK, OAT and HERO-2 trials and he was the chair of the myocardial infarction adjudication committee and ECG sub-study for HERO-2. As part of a continuing interest in molecular medicine John has established the cardiac genetics clinics with the genetics department, and is a member of TRAGADY. John has co-authored >120 peer-reviewed publications and six book chapters. He has supervised a number of MD and MHSc postgraduate students and has been invited speaker at recent American College and American Heart Association meetings.
Prof Jonathan Kalman
An internationally respected Electrophysiologist, Professor Jonathan Kalman is one of the leading heart rhythm experts in Australia. Professor Kalman is head of the Royal Melbourne Heart Rhythm department which is internationally renowned for the high quality of clinical medicine and investigative research performed.
Professor Kalman is currently the Scientific Chair of the Cardiac Society of Australia and New Zealand and also the Scientific Chair of the Asia Pacific Heart Rhythm Society. He is a Fellow of the Australasian College of Physicians, a Fellow of the American College of Cardiologists, and a Fellow of the Heart Rhythm Society. He is Professor of Medicine at The Royal Melbourne Hospital in Melbourne where he has made his unit a center of clinical, teaching and research excellence in Cardiovascular Electrophysiology